Blog

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Photo tsaken from Samarpana Chakraborty/X

Aug 10, 2024, 13:03

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Samarpana Chakraborty, Postdoctoral Researcher at Albert Einstein College of Medicine shared a post by Aditi Shastri, Associate Professor at Albert Einstein College of Medicine on X:

“Thrilled to share my postdoctoral work on STAT3 degraders in Venetoclax resistant AML. Grateful to Shastri lab and Aditi Shastri for giving me the opportunity to work on this fantastic project. ”

Quoting Aditi Shastri’s post:

“A new manuscript from shastri lab just dropped “A STAT3 Degrader Demonstrates Preclinical Efficacy in Venetoclax Resistant AML”. Congratulations to first author Samarpana Chakraborty and a huge thanks to amazing collabs and Kymera Therapeutics, EinsteinSCI, and Montefiore Health System.”

Source: Samarpana Chakraborty/X and Aditi Shastri/X

Aditi Shastri Albert Einstein College of Medicine cancer EinsteinSCI Kymera Therapeutics Montefiore Health System OncoDaily Oncology Samarpana Chakraborty

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage